home.aspx
 
EVENTS

SiriusDecisions 2019 Technology Exchange
SIRIUSDECISIONS 2019 TECHNOLOGY EXCHANGE
December 09-11, 2019
The drive for growth never ceases for b-to-b organizations, and more than ever technology is at the centre of enabling that progress. Gone are the days however when a disparate, disconnected set of platforms strewn across sales, marketing an product can serve the organization effectively. An aligned...

BIOFIT 2019
BIOFIT 2019
December 10-11, 2019
With the highest attending rate of academics, TTOs and research institutions, BioFIT is the place where academia-industry collaborations get started. BioFIT has taken on a whole new dimension becoming the meeting point in Europe for tech transfer and for sourcing early-stage innovations stemming fro...

Alexion Pharmaceuticals, Inc.

At Alexion, our mission is to serve patients and families affected by rare diseases. Since our founding, we have given hope to people who had none and shined a light on those who felt isolated and alone. But we know that fighting rare diseases takes so much more than hope. It requires persistence, dedication, and a relentless pursuit of the highest levels of medical innovation. At Alexion, our goal is to deliver medical breakthroughs where none currently exist.

RELATED NEWS


Alexion’s rare disease drug Soliris has a new indication after the FDA approved it for a disease that attacks the optic nerves.Approval of Soliris (eculizumab) for  neuromyelitis optica spectrum disorder (NMOSD) in adults who have the anti-aquaporin-4 antibody opens up further revenues for Alexion, which has already built a blockbuster franchise around the drug. Although only approved in a handful of rare diseases, the complement-inhibiting drug generated $962 million for Alexion in Q...

READ MORE

Alexion Pharmaceuticals is a company focused on ultra-rare diseases, although it is working on a shift into rare diseases. This may sound like something of a minor shift, but it represents developing drugs for more diseases with larger patient populations. The company’s success has been built primarily on its Soliris (eculizumab), a complement inhibitor. The drug has been approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical Hemolytic Uremic Syndrome (aHUS) and for generalized M...

READ MORE

The federal government’s probe into pharma’s co-pay assistance charities has snared some of the biggest names in the business, and Thursday the Department of Justice said three drugmakers have inked settlements totaling $122.6 million. Jazz, Lundbeck and Alexion each struck deals with the DOJ—worth $57 million, $52.6 million and $13 million, respectively—to resolve allegations of using payments to charities as “conduits” to help Medicare and other patients aff...
FIERCEPHARMA
READ MORE

Alexion has partnered with Sema4 to leverage their shared experience in data science and systems biology to accelerate rare disease diagnosis and therapeutic discovery. This new partnership will combine Alexion's rare disease SmartPanel analytics with Sema4's sequencing and genomic interpretation to further enable novel diagnostic and therapeutic insights into rare diseases. The world-class sequencing capabilities at Sema4 coupled with Alexion's SmartPanel analytics will enable a comprehensive e...

READ MORE

EVENTS

BIOFIT 2019
BIOFIT 2019
December 10-11, 2019
With the highest attending rate of academics, TTOs and research institutions, BioFIT is the place where academia-industry collaborations get started. BioFIT has taken on a whole new dimension becoming the meeting point in Europe for tech transfer and for sourcing early-stage innovations stemming fro...

eyeforpharma Awards 2019
EYEFORPHARMA AWARDS 2019
December 11-11, 2019
You’ll already know if you’re a winner: your patients are telling you. But now it’s time to be recognised by your peers and the wider healthcare community. The eyeforpharma awards are unique. They’re the only awards that focus exclusively on what matters - value for patients ...